UNSPSC 51384618: Suxibuzone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C24H26N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86TDZ5WP2B, chemically known as 3,5-pyrazolidinedione, 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-, hydrogen succinate (ester) but generally known as suxibuzone, which bears US NIH Compound Identifier 5362. European Medicines Agency schedules Suxibuzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10789MIG.

UNSPSC 51384618 Suxibuzone is a Commodity code that captures pharmaceutical products and related health-system supplies procured by state and local jurisdictions, though recent opportunities under this code reflect a broader range of pharmaceutical and pharmacy-benefit activities rather than suxibuzone specifically. State and local buyers under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work solicited includes procurement of naloxone and drug-deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and exploratory contracting for direct-to-manufacturer pharmacy benefit programs.

Recent activity appears concentrated in Florida, Minnesota, and Texas. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with pricing weighted heavily on competitiveness (75 percent) and products available through three authorized wholesalers. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013, April 3, 2026) to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage market research before formal procurement in the pharmacy-benefit space.